Company: MDCXW
Filing Date: 2025-06-13
Form Type: PRE 14A
Source: 0001062993-25-011673
Chunk: 19

Company: Medicus Pharma Ltd.
Filing Date: 2025-06-13
Form: PRE 14A
Chunk 19
---
 "" the special resolution authorizing the Board to approve a consolidation or share split in Proposal 5, and " the Chairman Amendment in Proposal 6.

<div align='center'>PRESENTATION OF FINANCIAL STATEMENTS</div>

The Company's audited consolidated financial statements as of and for the years ended December 31, 2024 and December 31, 2023, together with the auditor's report thereon, will be presented to the Shareholders at the Meeting. The Company's audited consolidated financial statements as of and for the years ended December 31, 2024 and December 31, 2023 are also available on the Company's website at www.medicuspharma.com.

<div align='center'>- 17 -</div>

Audit Committee Report

The material in this report is not "soliciting material," is not deemed "filed" with the SEC, and is not to be incorporated by reference into any filing by Medicus Pharma Ltd. under the Securities Act of 1933, as amended, or the Exchange Act.

The audit committee of the Board (the "Audit Committee") has reviewed and discussed the audited financial statements for the year ended December 31, 2024 with management. The Audit Committee has also discussed with EisnerAmper LLP ("EisnerAmper"), the Company's prior independent registered public accounting firm, the matters required to be discussed under applicable auditing standards, including Auditing Standard No. 1301. In addition, the Audit Committee discussed with EisnerAmper its independence, and received from EisnerAmper the written disclosures and the letter required by applicable requirements of the Public Company Accounting Oversight Board. Finally, the Audit Committee discussed with EisnerAmper, with and without management present, the scope and results of EisnerAmper's audit of such financial statements.

Based on these reviews and discussions, the Audit Committee recommended to the Board that such audited financial statements be included in the Company's Annual Report on Form 10-K for the year ended December 31, 2024.

Audit Committee of the Board

Mr. Robert J. Ciaruffoli (Chair)

Mr. Barry Fishman

Mr. Frank Lavelle

Dr. Sara R. May

<div align='center'>PROPOSAL 1 - APPOINTMENT AND REMUNERATION OF AUDITORS</div>

The members of the Audit Committee and the Board believe the replacement of EisnerAmper with KPMG as our independent registered accounting